Overview

Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

Status:
Withdrawn
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
To test whether specific aspects of the attention-enhancing effects of nicotine may be mediated by down-stream activation of alpha1 adrenoceptors, the interaction of nicotine and the alpha1 adrenergic antagonist prazosin on cognitive task performance will be tested in human non-smokers. The effects of a low-dose nicotine patch vs. a placebo patch will be tested in the presence and absence of prazosin over 4 test sessions.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Treatments:
Nicotine
Prazosin